WES Q1 2026 Earnings Call Transcript

Western Midstream reported record Q1 adjusted EBITDA of $683 million, up 15% year over year, and distributable cash flow of $509 million, while declaring a $0.93/unit distribution. Management expects 2026 adjusted EBITDA and DCF to land at the high end of prior guidance ranges, excluding the newly announced $1.6 billion Brazos Delaware II acquisition. The deal adds 470,000 dedicated acres and 460 MMcf/d of processing capacity, supporting a pro forma leverage profile near 3x and reinforcing the company’s growth outlook.

Analysis

WES is transitioning from a pure fee-based midstream story into a capacity-optimization and optionality story. The key second-order effect is that the Brazos purchase is less about headline EBITDA and more about reducing basis risk on the Delaware system: unused processing headroom plus contiguous acreage should let WES convert future volume upside into cash flow without a commensurate jump in maintenance capex. That matters because the market usually underwrites MLPs on near-term coverage, but the real value here is the ability to keep leverage near 3x while compounding distribution growth through 2027.

The bigger setup is that Waha dysfunction is temporarily suppressing throughput, but that creates a deferred-volume release valve once takeaway improves later this year. If even part of that curtailed gas returns, WES gets a double benefit: higher volumes and better fixed-recovery economics on excess NGLs and skim oil, which are disproportionately powerful to margins in a high-price tape. That makes the next two quarters more of a bridge than a peak; the market may be underestimating how much of the 2026 upside is actually a prelude to a stronger 2027 cash flow inflection from Brasos, Pathfinder, and North Loving II.

The contrarian risk is execution overload, not commodity exposure. WES is layering a bolt-on integration on top of two large organic builds while pushing into new ventures that are still pre-commercial; if project slippage or cost inflation hits, the market could rerate the stock from "show-me growth" to "multiple-capex trap" despite the attractive yield. The other hidden risk is that elevated commodity prices are supporting current margins, but if the strip rolls over before takeaway normalizes, the volume recovery thesis gets delayed and the distribution story becomes more yield-defensive than growth-driven.

Key Decisions for Investors

• Long WES common into any post-deal-close volatility over the next 4-8 weeks; the setup is asymmetric because Brazos adds cash flow with limited balance-sheet strain, while leverage should stay near 3x. Target is rerating on distribution coverage expansion rather than pure EBITDA growth.
• Buy WES Jan-2027 calls or call spreads on pullbacks; the best catalyst window is 2H26 to early 2027 when curtailments ease, Pathfinder starts contributing, and Brazos synergies become visible. Risk/reward favors options because near-term headlines may stay noisy while the real cash flow inflection is delayed.
• Pair trade: long WES / short OKE or another higher-multiple midstream peer if you want to isolate Delaware Basin asset quality and yield coverage. WES has a clearer path to self-funded distribution growth with more visible fee-based upside, while the market may still be paying for broader geographic diversification elsewhere.
• Avoid chasing after a spike tied to commodity strength; if WES moves on spot gas/oil headlines, trim into strength because a lot of the current upside is strip-dependent and could mean-revert before the volume thesis is realized.